Enming Cui1,2, Wansheng Long1, Juanhua Wu3, Qing Li4, Changyi Ma1, Yi Lei5, Fan Lin6. 1. Department of Radiology, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of SUN YAT-SEN University, Jiangmen Clinical Medical School of Guangdong Medical University, 23 Beijie Haibang Street, Jiangmen, 529030, People's Republic of China. 2. Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation, Guangzhou, People's Republic of China. 3. Department of Hepatobiliary Surgery, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of SUN YAT-SEN University, 23 Beijie Haibang Street, Jiangmen, 529030, People's Republic of China. 4. Department of Pathology, Jiangmen Central Hospital, Affiliated Jiangmen Hospital of SUN YAT-SEN University, 23 Beijie Haibang Street, Jiangmen, 529030, People's Republic of China. 5. Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, 3002 SunGangXi Road, Shenzhen, 518035, People's Republic of China. 6. Department of Radiology, The First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen Second People's Hospital, 3002 SunGangXi Road, Shenzhen, 518035, People's Republic of China. foxetfoxet@gmail.com.
Abstract
PURPOSES: To develop and externally validate a multiphase computed tomography (CT)-based machine learning (ML) model for staging liver fibrosis (LF) by using whole liver slices. MATERIALS AND METHODS: The development dataset comprised 232 patients with pathological analysis for LF, and the test dataset comprised 100 patients from an independent outside institution. Feature extraction was performed based on the precontrast (PCP), arterial (AP), portal vein (PVP) phase, and three-phase CT images. CatBoost was utilized for ML model investigation by using the features with good reproducibility. The diagnostic performance of ML models based on each single- and three-phase CT image was compared with that of radiologists' interpretations, the aminotransferase-to-platelet ratio index, and the fibrosis index based on four factors (FIB-4) by using the receiver operating characteristic curve with the area under the curve (AUC) value. RESULTS: Although the ML model based on three-phase CT image (AUC = 0.65-0.80) achieved higher AUC value than that based on PCP (AUC = 0.56-0.69) and PVP (AUC = 0.51-0.74) in predicting various stage of LF, significant difference was not found. The best CT-based ML model (AUC = 0.65-0.80) outperformed the FIB-4 in differentiating advanced LF and cirrhosis and radiologists' interpretation (AUC = 0.50-0.76) in the diagnosis of significant and advanced LF. CONCLUSION: All PCP, PVP, and three-phase CT-based ML models can be an acceptable in assessing LF, and the performance of the PCP-based ML model is comparable to that of the enhanced CT image-based ML model.
PURPOSES: To develop and externally validate a multiphase computed tomography (CT)-based machine learning (ML) model for staging liver fibrosis (LF) by using whole liver slices. MATERIALS AND METHODS: The development dataset comprised 232 patients with pathological analysis for LF, and the test dataset comprised 100 patients from an independent outside institution. Feature extraction was performed based on the precontrast (PCP), arterial (AP), portal vein (PVP) phase, and three-phase CT images. CatBoost was utilized for ML model investigation by using the features with good reproducibility. The diagnostic performance of ML models based on each single- and three-phase CT image was compared with that of radiologists' interpretations, the aminotransferase-to-platelet ratio index, and the fibrosis index based on four factors (FIB-4) by using the receiver operating characteristic curve with the area under the curve (AUC) value. RESULTS: Although the ML model based on three-phase CT image (AUC = 0.65-0.80) achieved higher AUC value than that based on PCP (AUC = 0.56-0.69) and PVP (AUC = 0.51-0.74) in predicting various stage of LF, significant difference was not found. The best CT-based ML model (AUC = 0.65-0.80) outperformed the FIB-4 in differentiating advanced LF and cirrhosis and radiologists' interpretation (AUC = 0.50-0.76) in the diagnosis of significant and advanced LF. CONCLUSION: All PCP, PVP, and three-phase CT-based ML models can be an acceptable in assessing LF, and the performance of the PCP-based ML model is comparable to that of the enhanced CT image-based ML model.
Authors: Richard K Sterling; Eduardo Lissen; Nathan Clumeck; Ricard Sola; Mendes Cassia Correa; Julio Montaner; Mark S Sulkowski; Francesca J Torriani; Doug T Dieterich; David L Thomas; Diethelm Messinger; Mark Nelson Journal: Hepatology Date: 2006-06 Impact factor: 17.425
Authors: Paul A Yushkevich; Joseph Piven; Heather Cody Hazlett; Rachel Gimpel Smith; Sean Ho; James C Gee; Guido Gerig Journal: Neuroimage Date: 2006-03-20 Impact factor: 6.556
Authors: W Ray Kim; Thomas Berg; Tarik Asselah; Robert Flisiak; Scott Fung; Stuart C Gordon; Harry L A Janssen; Pietro Lampertico; Daryl Lau; Jeffrey D Bornstein; Raul E Aguilar Schall; Phillip Dinh; Leland J Yee; Eduardo B Martins; Seng Gee Lim; Rohit Loomba; Jörg Petersen; Maria Buti; Patrick Marcellin Journal: J Hepatol Date: 2015-12-02 Impact factor: 25.083
Authors: Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok Journal: Hepatology Date: 2003-08 Impact factor: 17.425